Biomimetic delivery of emodin via macrophage membrane-coated UiO-66-NH2 nanoparticles for acute pancreatitis treatment
Biochemical and Biophysical Research Communications · 2024
DOI: 10.1016/j.bbrc.2024.149649 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Liuxuan Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, China; Department of Clinical Pharmacy, School of Pharmacy, …. Hauptthemen laut MEDLINE: Pancreatitis, Emodin, Organometallic Compounds, Nanoparticles. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National College Students Innovation and Entrepreneurship Training Program.
Abstract (Originalsprache)
Acute pancreatitis (AP) is a severe inflammatory condition with a rising incidence and high mortality rates, especially in severe cases. Emodin (ED), known for its potent anti-inflammatory properties, holds promise in addressing AP. However, its clinical application is hindered by limitations such as low bioavailability and insufficient target specificity. Herein, we developed a novel drug delivery system using macrophage membrane-coated UiO-66-NH2 nanoparticles loaded with ED (MVs-UiO-ED). UiO-66-NH2 was successfully synthesized and characterized, revealing an octahedral structure with a suitable size distribution. The successful loading of ED onto UiO-66-NH2 was confirmed by ultraviolet and infrared spectroscopy. Subsequently, MVs-UiO-ED was prepared by coating macrophage membrane-derived vesicles onto UiO-ED, resulting in a biomimetic delivery system. In vitro release studies demonstrated that MVs-UiO-ED exhibited a sustained-release profile, indicating its potential for prolonged drug circulation. An AP mouse model was established to evaluate the therapeutic efficacy of MVs-UiO-ED. Compared with the model group, MVs-UiO-ED significantly reduced serum levels of α-amylase and lipase, two indicators of pancreatitis severity. Furthermore, histopathological examinations revealed that MVs-UiO-ED ameliorated pancreatic tissue damage. This study underscores the potential of MVs-UiO-ED as an effective therapeutic approach for AP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, China; Department of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, China.
- Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, 621000, China.
- Department of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, China.
- Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, China. Electronic address: meilzhou@163.com.
Förderung
- National Natural Science Foundation of China
- National College Students Innovation and Entrepreneurship Training Program
Zitieren
APA
Yang, L., Liu, X., Yang, J., Wang, K., Ai, Z., Shang, J., & Zhou, M. (2024). Biomimetic delivery of emodin via macrophage membrane-coated UiO-66-NH2 nanoparticles for acute pancreatitis treatment. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2024.149649
Vancouver
Yang L, Liu X, Yang J, Wang K, Ai Z, Shang J, et al. Biomimetic delivery of emodin via macrophage membrane-coated UiO-66-NH2 nanoparticles for acute pancreatitis treatment. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2024.149649
BibTeX
@article{Yang2024,
author = {Yang, Liuxuan and Liu, Xianbin and Yang, Jing and Wang, Ke and Ai, Zhenghao and Shang, Jinlu and Zhou, Meiling},
title = {Biomimetic delivery of emodin via macrophage membrane-coated UiO-66-NH2 nanoparticles for acute pancreatitis treatment},
journal = {Biochemical and Biophysical Research Communications},
year = {2024},
doi = {10.1016/j.bbrc.2024.149649}
}
EUVIMED